Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: sso who wrote (179)	3/5/2002 10:56:57 PM
From: Biomaven	Read Replies (1) \| Respond to of 508

sso, I don't see infergen as primarily a hospital drug. Seems to me they'd need a GI/hepatologist sales force as well. But of course I agree with RKRW that ultimately what matters is getting good drugs approved. I do get concerned that they might be spreading themselves too thin, and another drug would only exacerbate this. However none of my concerns are enough to stop me believing that this remains one of the best stories in biotech. Peter